4902 Eisenhower Boulevard
Suite 125
Tampa, FL 33634
United States
813 286 7900
https://www.oragenics.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 5
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Charles L. Pope CPA | Executive Chairman | 112,5k | N/D | 1952 |
Mr. Joseph Michael Redmond | President & Interim Principal Executive Officer | N/D | N/D | 1961 |
Ms. Janet Huffman | CFO, Secretary & Treasurer | 314,9k | N/D | 1972 |
Dr. James P. Kelly M.A., M.D. | Chief Medical Officer & Member of Scientific Advisor | N/D | N/D | N/D |
Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
L'ISS Governance QualityScore di Oragenics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.